ReNeuron Group plc (LON:RENE – Get Free Report) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 3.38 ($0.04) and traded as low as GBX 3.28 ($0.04). ReNeuron Group shares last traded at GBX 3.38 ($0.04), with a volume of 177,373 shares.
ReNeuron Group Price Performance
The firm has a fifty day moving average of GBX 3.38 and a 200 day moving average of GBX 3.38. The company has a current ratio of 1.51, a quick ratio of 2.02 and a debt-to-equity ratio of 14.25. The company has a market capitalization of £1.93 million, a P/E ratio of -37.50 and a beta of 0.83.
About ReNeuron Group
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease.
Read More
- Five stocks we like better than ReNeuron Group
- What Does a Stock Split Mean?
- Energy Vault Soars 100%: CEO Shares Why in MarketBeat Exclusive
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Meta’s Q3 Earnings Beat—Is This Dip a Golden Entry Opportunity?
- NYSE Stocks Give Investors a Variety of Quality Options
- Top Nuclear Stocks Thriving on Soaring Energy Demand
Receive News & Ratings for ReNeuron Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReNeuron Group and related companies with MarketBeat.com's FREE daily email newsletter.
